MDT

96.87

+0.54%↑

A

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

A

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

A

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

A

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

MDT

96.87

+0.54%↑

A

146.9

-0.44%↓

VEEV

230.21

-2.17%↓

HQY

83.08

-3.5%↓

PHR.US

16.31

-4.06%↓

Search

Simulations Plus Inc

Atvērts

SektorsVeselības aprūpe

18.91 0.96

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

17.6

Max

19.02

Galvenie mērījumi

By Trading Economics

Ienākumi

-681K

Pārdošana

17M

P/E

Sektora vidējais

48.528

87.826

EPS

-0.034

Dividenžu ienesīgums

0.48

Peļņas marža

-3.9

Darbinieki

212

EBITDA

-79M

-74M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+5.26% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.26%

Nākamie ieņēmumi

2026. g. 2. apr.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

19M

387M

Iepriekšējā atvēršanas cena

17.95

Iepriekšējā slēgšanas cena

18.91

Ziņu noskaņojums

By Acuity

50%

50%

173 / 370 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 12. janv. 23:54 UTC

Tirgus saruna

CBA Could Underperform Again in 2026 -- Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 23:48 UTC

Tirgus saruna

Nikkei May Rise on Weaker Yen -- Market Talk

2026. g. 12. janv. 23:43 UTC

Tirgus saruna

Gold Edges Lower on Likely Technical Correction -- Market Talk

2026. g. 12. janv. 23:18 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

2026. g. 12. janv. 21:56 UTC

Tirgus saruna

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 12. janv. 21:50 UTC

Tirgus saruna
Peļņas

Auto & Transport Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 21:18 UTC

Tirgus saruna

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

2026. g. 12. janv. 20:54 UTC

Peļņas

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

2026. g. 12. janv. 20:48 UTC

Tirgus saruna

Oil Futures Settle Higher in Choppy Trade -- Market Talk

2026. g. 12. janv. 20:33 UTC

Tirgus saruna

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

2026. g. 12. janv. 20:18 UTC

Iegādes, apvienošanās, pārņemšana

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

2026. g. 12. janv. 19:39 UTC

Tirgus saruna

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Gold and Silver Set New Records on Fed Probe -- Market Talk

2026. g. 12. janv. 19:36 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 12. janv. 19:33 UTC

Tirgus saruna

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

2026. g. 12. janv. 19:24 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

2026. g. 12. janv. 19:22 UTC

Iegādes, apvienošanās, pārņemšana

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

2026. g. 12. janv. 18:21 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

2026. g. 12. janv. 18:20 UTC

Iegādes, apvienošanās, pārņemšana

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

2026. g. 12. janv. 18:19 UTC

Tirgus saruna

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

2026. g. 12. janv. 18:16 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 12. janv. 18:09 UTC

Tirgus saruna

Baidu's Outlook Bodes Well For Shares -- Market Talk

2026. g. 12. janv. 18:01 UTC

Iegādes, apvienošanās, pārņemšana

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

2026. g. 12. janv. 18:00 UTC

Tirgus saruna

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

5.26% augšup

Prognoze 12 mēnešiem

Vidējais 19 USD  5.26%

Augstākais 19 USD

Zemākais 19 USD

Pamatojoties uz 5 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

5 ratings

2

Pirkt

3

Turēt

0

Pārdot

Noskaņojums

By Acuity

173 / 370 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat